Education
About Us
Working with TipRanks
Follow Us
Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
CTNM Stock Chart & Stats
$12.22
-$0.71(-5.12%)
At close: 4:00 PM EST
$12.22
-$0.71(-5.12%)
Day’s Range― - ―
52-Week Range$3.35 - $16.33
Previous CloseN/A
Volume54.82K
Average Volume (3M)170.88K
Market Cap
$473.61M
Enterprise Value$377.21M
Total Cash (Recent Filing)$262.90M
Total Debt (Recent Filing)$8.25M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
May 14, 2026EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding32,673,534
10 Day Avg. Volume105,448
30 Day Avg. Volume170,880
Financial Highlights & Ratios
PEG Ratio11.51
Price to Book (P/B)1.21
Price to Sales (P/S)0.00
P/FCF Ratio-5.70
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.54K
Enterprise Value/Ebitda-5.92
Forecast
1Y Price Target
$20.80Price Target Upside70.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.2
Revenue Forecast (FY)$2.83M
Bulls Say, Bears Say
Bulls Say
Balance Sheet And Program RunwayCash runway that extends beyond the expected completion of PROPEL-IPF supports continued development without immediate need for additional financing, reducing near-term dilution risk.
Idiopathic Pulmonary Fibrosis DevelopmentPatient dosing in the Phase 2 PROPEL-IPF trial with lung function as the primary endpoint enables a direct efficacy comparison to a competitor and could materially affect the program's valuation if results are positive.
Safety And Dosing ProfileClinical data show PIPE-791 has a clean safety profile and sustained central receptor occupancy that support once-daily oral dosing, which could improve patient adherence and commercial appeal.
Bears Say
Exploratory Pain Study LimitationsThe short-duration exploratory design of the chronic pain trial is intended for early signal detection only, so absence of a clear pain signal would provide limited insight into commercial potential.
Limited Trial PowerThe Phase 1b study's small patient numbers and brief treatment period mean the readout is likely qualitative and may not detect a statistically significant drug effect, limiting confidence in efficacy signals.
PIPE-307 Efficacy Concern In MSPIPE-307 was generally well tolerated but did not show a meaningful benefit on an exploratory vision-related measure in relapsing-remitting multiple sclerosis, raising questions about efficacy in that indication.
Contineum Therapeutics, Inc. Class A News
CTNM FAQ
What was Contineum Therapeutics, Inc. Class A’s price range in the past 12 months?
Contineum Therapeutics, Inc. Class A lowest stock price was $3.35 and its highest was $16.33 in the past 12 months.
What is Contineum Therapeutics, Inc. Class A’s market cap?
Contineum Therapeutics, Inc. Class A’s market cap is $473.61M.
When is Contineum Therapeutics, Inc. Class A’s upcoming earnings report date?
Contineum Therapeutics, Inc. Class A’s upcoming earnings report date is May 14, 2026 which is in 55 days.
How were Contineum Therapeutics, Inc. Class A’s earnings last quarter?
Contineum Therapeutics, Inc. Class A released its earnings results on Mar 05, 2026. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.389 by -$0.101.
Is Contineum Therapeutics, Inc. Class A overvalued?
According to Wall Street analysts Contineum Therapeutics, Inc. Class A’s price is currently Undervalued.
Does Contineum Therapeutics, Inc. Class A pay dividends?
Contineum Therapeutics, Inc. Class A does not currently pay dividends.
What is Contineum Therapeutics, Inc. Class A’s EPS estimate?
Contineum Therapeutics, Inc. Class A’s EPS estimate is -0.53.
How many shares outstanding does Contineum Therapeutics, Inc. Class A have?
Contineum Therapeutics, Inc. Class A has 32,673,534 shares outstanding.
What happened to Contineum Therapeutics, Inc. Class A’s price movement after its last earnings report?
Contineum Therapeutics, Inc. Class A reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.389. Following the earnings report the stock price went up 0.507%.
Which hedge fund is a major shareholder of Contineum Therapeutics, Inc. Class A?
Currently, no hedge funds are holding shares in CTNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Contineum Therapeutics, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.80 (70.21% Upside)
$20.80 (70.21% Upside)
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.0%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.24%
12-Months-Change
Fundamentals
Return on Equity
-30.40%
Trailing 12-Months
Asset Growth
-17.38%
Trailing 12-Months
Company Description
Contineum Therapeutics, Inc. Class A
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
CTNM Stock 12 Month Forecast
Average Price Target
$20.80
▲(70.21% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Alpha Tau Medical Ltd
―
Immuneering
―
enGene Holdings
―
Ownership Overview
0.58% Insiders
7.97% Mutual Funds
56.01% Other Institutional Investors
30.47% Public Companies and
Individual Investors